Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 21, 2014; 20(27): 9170-9177
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.9170
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.9170
Figure 1 Cumulative probability of avoiding infliximab dose intensification.
The data below indicate the number and percent of patients at risk. Comparison using the Breslow test. CD: Crohn’s disease; UC: Ulcerative colitis.
- Citation: Taxonera C, Olivares D, Mendoza JL, Díaz-Rubio M, Rey E. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2014; 20(27): 9170-9177
- URL: https://www.wjgnet.com/1007-9327/full/v20/i27/9170.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i27.9170